PD-L1基因表达的调控机制  

The regulatory mechanism of PD-L1 gene expression

作　　者：王梦媛 裴晏梓 谭理 WANG Mengyuan;PEI Yanzi;TAN Li(Laboratory of Epigenetics,Institute of Biomedical Sciences,Fudan University,Shanghai 200032,China;Zhongshan Hospital,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学生物医学研究院表观遗传学实验室,上海200032 [2]复旦大学附属中山医院,上海200032

出　　处：《生命的化学》2020年第10期1683-1692,共10页Chemistry of Life

基　　金：国家自然科学基金项目(81672785,31871291);国家重点研究发展计划(2016YFA0101800)。

摘　　要：程序性死亡配体-1(programmed death ligand-1,PD-L1)在人类多种恶性肿瘤细胞中高表达。肿瘤细胞上的PD-L1与T细胞上的PD-1结合从而抑制T细胞活性,导致肿瘤免疫逃逸。阻断PD-1/PD-L1相互作用的抗体有助于重新激活细胞毒性T细胞,从而消灭癌细胞。近年来,临床上针对PD-1/PD-L1免疫检查点的药物在人类癌症治疗中卓有成效。阐明PD-L1基因表达调控的分子机制可以加深对肿瘤免疫逃逸机理的认识,对临床肿瘤免疫治疗具有重要意义。本文主要从基因变异、表观遗传修饰、转录调控、microRNA与翻译后修饰等方面综述了PD-L1基因表达调控的研究进展。PD-L1 is highly expressed in various malignant tumors.PD-L1 binds to PD-1 on immune cells to inhibit the activation of cytotoxic T cells,which in turn facilitates the immune escape of tumor cells.In clinic,targeting the PD-1/PD-L1 checkpoint has been successfully applied in tumor immunotherapy.Therefore,understanding the regulatory mechanism of PD-L1 gene expression provides new strategies to improve the efficiency of anti-PD-1/PD-L1 therapy.Here,we summarize the research progress on the regulatory mechanisms of PD-L1 gene expression including genetic,epigenetic,transcriptional,post-transcriptional,translational,and post-translational regulation.

关 键 词：PD-L1 肿瘤免疫 分子调控 

分 类 号：R730.2[医药卫生—肿瘤]